JP2015231997A5 - - Google Patents

Download PDF

Info

Publication number
JP2015231997A5
JP2015231997A5 JP2015132999A JP2015132999A JP2015231997A5 JP 2015231997 A5 JP2015231997 A5 JP 2015231997A5 JP 2015132999 A JP2015132999 A JP 2015132999A JP 2015132999 A JP2015132999 A JP 2015132999A JP 2015231997 A5 JP2015231997 A5 JP 2015231997A5
Authority
JP
Japan
Prior art keywords
formulation
histidine
mannitol
formulation according
preparation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015132999A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015231997A (ja
Filing date
Publication date
Priority claimed from EP08170884A external-priority patent/EP2196476A1/en
Application filed filed Critical
Publication of JP2015231997A publication Critical patent/JP2015231997A/ja
Publication of JP2015231997A5 publication Critical patent/JP2015231997A5/ja
Withdrawn legal-status Critical Current

Links

JP2015132999A 2008-12-10 2015-07-01 抗体製剤 Withdrawn JP2015231997A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation
EP08170884.4 2008-12-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011540063A Division JP6143416B2 (ja) 2008-12-10 2009-12-09 抗体製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018102715A Division JP2018168158A (ja) 2008-12-10 2018-05-29 抗体製剤

Publications (2)

Publication Number Publication Date
JP2015231997A JP2015231997A (ja) 2015-12-24
JP2015231997A5 true JP2015231997A5 (Direct) 2016-02-25

Family

ID=40637230

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011540063A Active JP6143416B2 (ja) 2008-12-10 2009-12-09 抗体製剤
JP2015132999A Withdrawn JP2015231997A (ja) 2008-12-10 2015-07-01 抗体製剤
JP2018102715A Withdrawn JP2018168158A (ja) 2008-12-10 2018-05-29 抗体製剤
JP2020133477A Active JP7286595B2 (ja) 2008-12-10 2020-08-06 抗体製剤
JP2023085464A Pending JP2023109938A (ja) 2008-12-10 2023-05-24 抗体製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011540063A Active JP6143416B2 (ja) 2008-12-10 2009-12-09 抗体製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018102715A Withdrawn JP2018168158A (ja) 2008-12-10 2018-05-29 抗体製剤
JP2020133477A Active JP7286595B2 (ja) 2008-12-10 2020-08-06 抗体製剤
JP2023085464A Pending JP2023109938A (ja) 2008-12-10 2023-05-24 抗体製剤

Country Status (31)

Country Link
US (3) US20110236398A1 (Direct)
EP (4) EP2196476A1 (Direct)
JP (5) JP6143416B2 (Direct)
KR (2) KR20170044211A (Direct)
CN (3) CN104399076B (Direct)
AU (1) AU2009324371B2 (Direct)
BR (1) BRPI0922730A2 (Direct)
CA (1) CA2745938C (Direct)
CL (1) CL2011001406A1 (Direct)
CO (1) CO6361952A2 (Direct)
CY (2) CY1117735T1 (Direct)
DK (2) DK3072906T3 (Direct)
EC (1) ECSP11011192A (Direct)
ES (2) ES2579835T3 (Direct)
HR (2) HRP20160754T1 (Direct)
HU (2) HUE028408T2 (Direct)
IL (3) IL264316B2 (Direct)
LT (1) LT3072906T (Direct)
MA (1) MA33023B1 (Direct)
MX (1) MX2011006242A (Direct)
MY (2) MY157772A (Direct)
NZ (1) NZ592918A (Direct)
PE (1) PE20120342A1 (Direct)
PL (2) PL2376533T3 (Direct)
PT (2) PT2376533T (Direct)
RU (2) RU2563179C2 (Direct)
SI (2) SI2376533T1 (Direct)
SM (1) SMT201600222B (Direct)
TN (1) TN2011000229A1 (Direct)
WO (1) WO2010066762A1 (Direct)
ZA (1) ZA201103362B (Direct)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
AU2011219715B2 (en) 2010-02-26 2014-12-11 Novo Nordisk A/S Stable antibody containing compositions
ES2765418T3 (es) 2010-03-01 2020-06-09 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
JP6294075B2 (ja) 2010-05-28 2018-03-14 ノヴォ ノルディスク アー/エス 抗体及び防腐剤を含む安定した多用量組成物
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN103282042B (zh) 2010-09-17 2014-12-10 巴克斯特国际公司 通过具有组氨酸的水性制剂在弱酸性至中性pH稳定的免疫球蛋白
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
JP2014510730A (ja) 2011-03-16 2014-05-01 サノフイ デュアルv領域抗体様タンパク質の使用
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SI3682905T1 (sl) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi in nukleinske kisline ter njihove uporabe
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
WO2013082282A1 (en) 2011-12-02 2013-06-06 lNOVARTIS AG Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease.
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
CA2864539C (en) * 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
DK2825037T3 (da) * 2012-03-16 2019-07-29 Regeneron Pharma Gnavere, der udtrykker pH-sensitive immunoglobulinsekvenser
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
KR20240091288A (ko) * 2012-09-20 2024-06-21 모르포시스 아게 류마티스 관절염에 대한 치료
JP2016502526A (ja) * 2012-11-16 2016-01-28 ノバルティス アーゲー 末梢動脈疾患を処置するためのIL−1β結合抗体の使用
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
US20160002342A1 (en) * 2013-03-15 2016-01-07 Xinghang Ma Anti-prolactin receptor antibody formulations
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗il-4/抗il-13之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
WO2015181757A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
JP2017527560A (ja) * 2014-09-03 2017-09-21 メドイミューン・リミテッドMedImmune Limited 安定抗il−4rアルファ抗体配合物
US10155820B2 (en) 2014-11-12 2018-12-18 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
US11058769B2 (en) 2015-12-07 2021-07-13 Merck Patent Gmbh Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab
EP3909985A1 (en) * 2016-06-27 2021-11-17 MorphoSys AG Anti-cd19 antibody formulations
KR20190032436A (ko) * 2016-07-21 2019-03-27 노파르티스 아게 폐 유육종증의 증상을 치료하거나 완화하기 위한 il-1beta 결합 항체 카나키누맙의 용도
KR102546471B1 (ko) * 2016-09-27 2023-06-21 프레제니우스 카비 도이치란트 게엠베하 액상의 약학 조성물
RU2767793C2 (ru) 2016-11-18 2022-03-21 Астеллас Фарма Инк. НОВЫЙ Fab-ФРАГМЕНТ АНТИТЕЛА ПРОТИВ MUC1 ЧЕЛОВЕКА
JP2020524694A (ja) * 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのIL−1β結合性抗体
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類CEACAM5抗體Fab片段
CA3075711A1 (en) * 2017-09-13 2019-03-21 Novartis Ag Use of il-1 b binding antibodies for the treatment of alcoholic hepatitis
AU2019237252A1 (en) * 2018-03-23 2020-10-22 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
MX2020012351A (es) 2018-05-17 2021-01-29 Astellas Pharma Inc Complejo que tiene fragmento fab de anticuerpo anti-muc1 de humano, enlazador peptido y/o ligando.
SG11202103670XA (en) 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
US11634485B2 (en) * 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业(上海)股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
EP4268803A4 (en) * 2020-12-22 2025-04-16 Bio-Thera Solutions, Ltd. Stable antibody preparation, preparation method for same, and applications thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
CN102416176A (zh) 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
CA2411374C (en) 2000-06-29 2012-10-30 Abbott Laboratories Dual specificity antibodies and methods of making and using
WO2002011753A1 (en) * 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
NZ532896A (en) * 2001-11-08 2007-08-31 Pdl Biopharma Inc Stable liquid pharmaceutical formulation of IGG antibodies including daclizumab and fontolizumab
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
SI2335725T1 (sl) * 2003-04-04 2017-01-31 Genentech, Inc. Visokokoncentrirane formulacije protiteles in proteinov
CN101111264A (zh) * 2005-01-28 2008-01-23 惠氏公司 稳定化的液体多肽制剂
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
NZ561137A (en) * 2005-03-08 2011-09-30 Pharmacia & Upjohn Co Llc Stable anti-CTLA-4 antibody compositions with chelating agents
WO2006125207A2 (en) * 2005-05-19 2006-11-23 Amgen Inc. Compositions and methods for increasing the stability of antibodies
JP2009513645A (ja) 2005-10-26 2009-04-02 ノバルティス アクチエンゲゼルシャフト IL−1β化合物の新規使用
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
MX2009006199A (es) * 2006-12-11 2009-06-22 Hoffmann La Roche Formulacion parenteral de anticuerpos abeta.
EA200970880A1 (ru) * 2007-03-22 2010-02-26 Имклоун Элэлси Стабильные композиции на основе антител
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Similar Documents

Publication Publication Date Title
JP2015231997A5 (Direct)
TWI725973B (zh) 抗-cgrp抗體調配物
JP7473603B2 (ja) 液体医薬組成物
Maa et al. Influenza vaccine powder formulation development: spray‐freeze‐drying and stability evaluation
HRP20241131T1 (hr) Visokokoncentrirane formulacije inhibitornih antitijela masp-2 niske viskoznosti, pribori i metode
JP2021504372A5 (Direct)
JP2014514346A5 (Direct)
JP2013543505A5 (Direct)
RU2015132431A (ru) Составы, содержащие антитела
JP7229999B2 (ja) ダプトマイシン製剤
JP2016520075A5 (Direct)
CN101631563B (zh) 含有流感疫苗的冻干制剂及其制备方法
JP2019504086A5 (Direct)
PE20170780A1 (es) Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf
JP2019509311A5 (Direct)
JP2015519382A5 (Direct)
JP2013079270A5 (Direct)
JP2016505572A5 (Direct)
RU2011151286A (ru) Лиофилизированные рецептуры для малых модульных иммунофармацевтических средств
JP2019504882A5 (Direct)
JP2017531682A5 (Direct)
RU2016105462A (ru) Способы и композиции, которые обеспечивают модуляцию иммунных ответов, связанных с введением биофармацевтического лекарственного средства
JP2017516848A5 (Direct)
JP2017514868A5 (Direct)
JP2016539921A5 (Direct)